Oakbrook Investments LLC lowered its position in Bristol-Myers Squibb Co (NYSE:BMY) by 10.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 94,204 shares of the biopharmaceutical company’s stock after selling 10,450 shares during the quarter. Oakbrook Investments LLC’s holdings in Bristol-Myers Squibb were worth $6,005,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Bristol-Myers Squibb by 0.3% in the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after acquiring an additional 333,685 shares during the period. BlackRock Inc. grew its holdings in shares of Bristol-Myers Squibb by 2.4% in the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after purchasing an additional 2,367,864 shares during the last quarter. State Street Corp grew its holdings in shares of Bristol-Myers Squibb by 1.8% in the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares during the last quarter. Dodge & Cox grew its holdings in shares of Bristol-Myers Squibb by 1.6% in the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock worth $1,648,168,000 after purchasing an additional 459,271 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Bristol-Myers Squibb by 3.9% in the second quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after purchasing an additional 910,496 shares during the last quarter. 69.67% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently commented on BMY shares. SunTrust Banks upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price target on the stock in a report on Wednesday, November 1st. Barclays upped their price target on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a report on Friday, October 13th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. Finally, Leerink Swann upped their price target on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $65.05.
Shares of Bristol-Myers Squibb Co (BMY) traded up $0.46 during trading on Thursday, reaching $62.47. 5,064,800 shares of the company’s stock traded hands, compared to its average volume of 5,460,000. Bristol-Myers Squibb Co has a one year low of $46.01 and a one year high of $66.10. The company has a market cap of $102,240.00, a PE ratio of 24.59, a price-to-earnings-growth ratio of 2.22 and a beta of 1.18. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter in the prior year, the business posted $0.77 earnings per share. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. research analysts predict that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be issued a $0.40 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.99%.
In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Oakbrook Investments LLC Has $6.01 Million Stake in Bristol-Myers Squibb Co (NYSE:BMY)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/11/bristol-myers-squibb-company-bmy-stake-lessened-by-oakbrook-investments-llc.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.